Literature DB >> 17994191

Effects of aripiprazole and terguride on dopamine synthesis in the dorsal striatum and medial prefrontal cortex of preweanling rats.

S D Iñiguez1, A M Cortez, C A Crawford, S A McDougall.   

Abstract

The purpose of this study was to determine whether aripiprazole, a D2-like partial agonist increasingly prescribed to children, alters DA synthesis via actions at autoreceptors in the dorsal striatum and medial prefrontal cortex (mPFC) of preweanling rats. The ability of dopaminergic agents to alter DOPA accumulation in the striatum and mPFC was measured after NSD-1015 on postnatal day (PD) 20. Dopaminergic tone was manipulated by administering reserpine, gamma-butyrolactone (GBL), or through amphetamine withdrawal. Results showed that the partial agonists aripiprazole and terguride increased striatal DOPA accumulation under normosensitive conditions, but decreased DOPA accumulation in states of low dopaminergic tone. A different pattern of results was observed in the mPFC, because terguride and haloperidol, but not aripiprazole, increased DOPA accumulation under normosensitive conditions. In conclusion, the present data show that aripiprazole affects striatal synthesis modulating autoreceptors in an adult-typical manner during the late preweanling period. Unlike in adult rats, however, the mPFC of preweanling rats appears to contain transitory synthesis modulating autoreceptors that are sensitive to drug manipulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994191     DOI: 10.1007/s00702-007-0820-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.850


  59 in total

1.  Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement.

Authors:  A M Barr; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  1999-01       Impact factor: 4.530

2.  Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse.

Authors:  Matthew W Feltenstein; C Anthony Altar; Ronald E See
Journal:  Biol Psychiatry       Date:  2006-06-27       Impact factor: 13.382

3.  Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.

Authors:  K Svensson; A Ekman; M F Piercey; W E Hoffmann; J T Lum; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

4.  Differential functional ontogeny of dopamine presynaptic receptor regulation.

Authors:  I A Shalaby; P S Dendel; L P Spear
Journal:  Brain Res       Date:  1981-06       Impact factor: 3.252

5.  Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys.

Authors:  Donna M Platt; Joshua S Rodefer; James K Rowlett; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2003-02-13       Impact factor: 4.530

6.  (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  Eur J Pharmacol       Date:  1984-10-30       Impact factor: 4.432

7.  The development of D2 autoreceptor-mediated modulation of K(+)-evoked dopamine release in the neostriatum.

Authors:  S L Andersen; R A Gazzara
Journal:  Brain Res Dev Brain Res       Date:  1994-03-18

8.  Effects of dopamine partial-agonist aminoergolines on dopamine metabolism in limbic and extrapyramidal regions of rat brain.

Authors:  R J Baldessarini; E R Marsh; D Huston-Lyons
Journal:  Biochem Pharmacol       Date:  1994-05-18       Impact factor: 5.858

9.  Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

Authors:  Kevin D Burris; Thaddeus F Molski; Cen Xu; Elaine Ryan; Katsura Tottori; Tetsuro Kikuchi; Frank D Yocca; Perry B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

10.  Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients.

Authors:  G U Corsini; U Bonuccelli; E Rainer; M Del Zompo
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

View more
  6 in total

1.  Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats.

Authors:  Taleen Der-Ghazarian; Sergios Charntikov; Fausto A Varela; Cynthia A Crawford; Sanders A McDougall
Journal:  J Neural Transm (Vienna)       Date:  2010-04-06       Impact factor: 3.575

2.  Fluoxetine exposure during adolescence alters responses to aversive stimuli in adulthood.

Authors:  Sergio D Iñiguez; Lyonna F Alcantara; Brandon L Warren; Lace M Riggs; Eric M Parise; Vincent Vialou; Katherine N Wright; Genesis Dayrit; Steven J Nieto; Matthew B Wilkinson; Mary K Lobo; Rachael L Neve; Eric J Nestler; Carlos A Bolaños-Guzmán
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

3.  Postnatal manganese exposure does not alter dopamine autoreceptor sensitivity in adult and adolescent male rats.

Authors:  Sanders A McDougall; Alena Mohd-Yusof; Graham J Kaplan; Zuhair I Abdulla; Ryan J Lee; Cynthia A Crawford
Journal:  Eur J Pharmacol       Date:  2013-02-28       Impact factor: 4.432

4.  Fluoxetine exposure in adolescent and adult female mice decreases cocaine and sucrose preference later in life.

Authors:  Francisco J Flores-Ramirez; Israel Garcia-Carachure; David O Sanchez; Celene Gonzalez; Samuel A Castillo; Miguel A Arenivar; Anapaula Themann; Omar Lira; Minerva Rodriguez; Joshua Preciado-Piña; Sergio D Iñiguez
Journal:  J Psychopharmacol       Date:  2018-10-18       Impact factor: 4.153

5.  Agonist and antagonist effects of aripiprazole on D₂-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone.

Authors:  Guo Fen Ma; Noora Raivio; Josefa Sabrià; Jordi Ortiz
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

6.  Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole.

Authors:  Ömer Başay; Burge Kabukcu Basay; Önder Öztürk; Zeki Yüncü
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-05-31       Impact factor: 2.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.